Dr. Rui joined the Division of Hematology/Oncology as an Assistant Professor in the Department of Medicine in December 2012. After receiving his Bachelor of Medicine degree from Wannan Medical College and nine years of clinical work in oncology at the Anhui Medical University in China, Dr. Rui went on to pursue his PhD in Chris Goodnow's lab at the Australian National University, where he investigated B cell antigen receptor signaling in B cell tolerance and tumorigenesis. In 2006, he received a CJ Martin Postdoctoral Fellowship and started lymphoma research in Louis Staudt's lab at the National Cancer Institute. His study revealed a new function of the Janus kinase JAK2 that targets the histone protein H3 and cooperates with the histone demethylase JMJD2C to promote cancer cell survival.
Dr. Rui's research in his lab continues to focus on lymphoma biology, with an emphasis on JAK-STAT signaling in lymphomagenesis. Deregulation of this pathway contributes to pathogenesis of Hodgkin lymphoma and Non-Hodgkin lymphoma, including aggressive diffuse large B-cell lymphoma. The goal of his research is to identify JAK and its downstream molecular targets for therapeutic applications to these cancers. In addition, his research interests include investigation of the F-box protein FBXO10, which he has recently characterized as a potential tumor suppressor.
American Society of Hematology
American Association for Cancer Research
Search for Lixin Rui's literature abstracts on PubMed
Lixin Rui, Roland Schmitz, Michele Ceribelli, and Louis M. Staudt. Malignant pirates of the immune system (review article). Nature Immunology 2011; 12 (10): 933-940.
Christian Steidl, Sohrab P. Shah, Bruce W. Woolcock, Lixin Rui, Masahiro Kawahara, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471 (7338): 377-381.
Lixin Rui, N. C. Tolga Emre, Michael J. Kruhlak, Hye-Jung Chung, Christian Steidl, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010; 18: 590-605.
Lixin Rui and Christopher C Goodnow. Lymphoma and the control of B cell growth and differentiation (review article). Current Molecular Medicine 2006; 6(3): 291-308
Carola G Vinuesa, Matthew C Cook, Constanza Angelucci, Vicki Athanasopoulos, Lixin Rui, Kim M Hill, Di Yu, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005; 435: 452-8
Lixin Rui, Carrola G Vinuesa, Julie Blasioli and Christopher C Goodnow. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nature Immunology 2003; 4(6): 594-600